Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) announced the decision to discontinue the development of cobiprostone based on the results of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE